XML 31 R19.htm IDEA: XBRL DOCUMENT
v3.25.2

STOCK PLANS | 6 Months Ended
--- | ---
Jun. 30, 2025
Stockholders' Equity Note [Abstract] |
STOCK PLANS | STOCK PLANS Stock Incentive Plans The Pacira BioSciences, Inc. Amended and Restated 2011 Stock Incentive Plan, or 2011 Plan, was originally adopted by its board of directors and approved by its stockholders in June 2011 and was amended and restated in June 2014, June 2016, June 2019, June 2021, June 2023 and June 2025. The June 2025 amendment and restatement and approval by the Company’s stockholders increased the number of shares of common stock authorized for issuance as equity awards under the 2011 Plan by 2,500,000 shares, which allows for the granting of incentive stock options, non-statutory stock options, restricted stock units and other stock-based awards. In April 2014, the Company’s board of directors approved and adopted the Company’s 2014 Inducement Plan (the “2014 Inducement Plan”), pursuant to which awards could be made to new employees under the 2014 Inducement Plan for up to 175,000 shares of the Company’s common stock as a material inducement to such persons entering into employment with the Company. In December 2023, the board of directors, upon recommendation of the people and compensation committee of the board of directors (the “P&C Committee”), adopted the Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan (as amended and restated, the “First A&R Inducement Plan”) such that, among other things, an additional 642,093 shares of the Company’s common stock were reserved for issuance. In September 2024, the board of directors, upon the recommendation of the P&C Committee, adopted the Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan (as amended and restated, the “Second A&R Inducement Plan”) to add an additional 707,907 shares of the Company’s common stock to bring the total amount of shares reserved for issuance under the Inducement Plan to 1,525,000. In January 2025, the board of directors, upon the recommendation of the P&C Committee, adopted the Pacira BioSciences, Inc. Amended and Restated 2014 Inducement Plan (as amended and restated to date, the “Inducement Plan”) to add an additional 785,000 shares of the Company’s common stock to bring the total amount of shares reserved for issuance under the Inducement Plan to 2,310,000, of which 250,007 shares remain available for issuance as of June 30, 2025, and extend the term of the Inducement Plan such that it will now expire on January 18, 2035. The Inducement Plan allows for the granting of nonstatutory stock options, restricted stock awards and other stock-based awards, and was adopted by the board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market Listing Rules. In accordance with this rule, awards under the Inducement Plan may only be made to an employee who has not previously been an employee or member of the board of directors or the board of directors of any parent or subsidiary, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary. Inducement Awards From time to time, the board of directors, upon recommendation of the P&C Committee, has approved individually negotiated grants of options and restricted stock units for certain of the Company’s officers in connection with their respective appointments, in each case, pursuant to the inducement plan in effect at such time. Stock-Based Compensation The Company recognized stock-based compensation expense in the periods presented as follows (in thousands):
|  | Three Months Ended June 30, |  | Six Months Ended June 30,
|  | 2025 |  | 2024 |  | 2025 |  | 2024
Cost of goods sold |  | $ | 1,682 |  |  | $ | 1,259 |  |  | $ | 3,398 |  |  | $ | 2,387 |
Research and development |  | 2,407 |  |  | 1,925 |  |  | 4,648 |  |  | 3,728 |
Selling, general and administrative |  | 11,383 |  |  | 8,848 |  |  | 21,979 |  |  | 16,833 |
Contingent consideration (gains) charges, acquisition-related expenses, restructuring and other |  | — |  |  | 492 |  |  | — |  |  | 2,727 |
Total |  | $ | 15,472 |  |  | $ | 12,524 |  |  | $ | 30,025 |  |  | $ | 25,675 |
Stock-based compensation from: |  |  |  |  |  |  |  |
Stock options |  | $ | 4,309 |  |  | $ | 5,796 |  |  | $ | 8,749 |  |  | $ | 12,525 |
Restricted stock units |  | 10,681 |  |  | 6,517 |  |  | 20,287 |  |  | 12,727 |
Employee stock purchase plan share options |  | 482 |  |  | 211 |  |  | 989 |  |  | 423 |
Total |  | $ | 15,472 |  |  | $ | 12,524 |  |  | $ | 30,025 |  |  | $ | 25,675 |
Equity Awards The following tables contain information about the Company’s stock option and restricted stock unit, or RSU, activity for the six months ended June 30, 2025:
Stock Options |  | Number of Stock Options |  | Weighted Average Exercise Price (Per Share)
Outstanding at December 31, 2024 |  | 6,845,618 |  |  | $ | 42.95 |
Granted |  | 432,632 |  |  | 25.45 |
Forfeited |  | (21,074) |  |  | 32.88 |
Expired |  | (414,815) |  |  | 55.29 |
Outstanding at June 30, 2025 |  | 6,842,361 |  |  | 41.12 |
Restricted Stock Units |  | Number of Restricted Stock Units |  | Weighted Average Grant Date Fair Value (Per Share)
Unvested at December 31, 2024 |  | 2,769,728 |  |  | $ | 32.07 |
Granted |  | 2,355,965 |  |  | 26.11 |
Vested |  | (722,131) |  |  | 37.04 |
Forfeited |  | (108,615) |  |  | 28.77 |
Unvested at June 30, 2025 |  | 4,294,947 |  |  | 28.05 |
The weighted average fair value of stock options granted during the six months ended June 30, 2025 was $13.81 per share. The fair values of stock options granted were estimated using the Black-Scholes option valuation model with the following weighted average assumptions:
Black-Scholes Weighted Average Assumption |  | Six Months Ended June 30, 2025
Expected dividend yield |  | None
Risk-free interest rate |  | 4.19%
Expected volatility |  | 57.8%
Expected term of options |  | 5.14 years
Employee Stock Purchase Plan The Company’s Amended and Restated 2014 Employee Stock Purchase Plan, or ESPP, features two six-month offering periods per year, running from January 1 to June 30 and July 1 to December 31. Under the ESPP, employees may elect to contribute after-tax earnings to purchase shares at 85% of the closing fair market value of the Company’s common stock on either the offering date or the purchase date, whichever is lesser. During the six months ended June 30, 2025, 100,728 shares were purchased and issued through the ESPP.

X
- Definition The entire disclosure of an entity's employee compensation and benefit plans, excluding share-based compensation and including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, life insurance, severance, health care, unemployment and other benefit plans. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/710/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 712 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/712/tableOfContent Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContent + Details
Name: | us-gaap_CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration